Nabilone Oral Capsule — Competitive Intelligence Brief

Nabilone Oral Capsule (Nabilone Oral Capsule) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic cannabinoid. Area: Oncology; Pain Management; Psychiatry.

marketed Synthetic cannabinoid CB1 and CB2 cannabinoid receptors Oncology; Pain Management; Psychiatry Small molecule

Target snapshot

Nabilone Oral Capsule (Nabilone Oral Capsule) — Centre for Addiction and Mental Health. Nabilone is a synthetic cannabinoid that mimics THC by binding to cannabinoid receptors in the central nervous system to produce antiemetic and analgesic effects.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nabilone Oral Capsule TARGET	Nabilone Oral Capsule	Centre for Addiction and Mental Health	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Cesamet™ (nabilone)	Cesamet™ (nabilone)	NEMA Research, Inc.	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Nabilone, flexible dosing	Nabilone, flexible dosing	University of Calgary	phase 3	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Nabilone Capsules	Nabilone Capsules	Eldon Loh, MD	phase 3	Synthetic cannabinoid	CB1 receptor, CB2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synthetic cannabinoid class)

1. Centre for Addiction and Mental Health · 1 drug in this class
2. Eldon Loh, MD · 1 drug in this class
3. NEMA Research, Inc. · 1 drug in this class
4. University of Calgary · 1 drug in this class